Whole MYBPC3 NGS sequencing as a molecular strategy to improve the efficiency of molecular diagnosis of patients with hypertrophic cardiomyopathy.


Journal

Human mutation
ISSN: 1098-1004
Titre abrégé: Hum Mutat
Pays: United States
ID NLM: 9215429

Informations de publication

Date de publication:
02 2020
Historique:
received: 26 08 2019
revised: 23 10 2019
accepted: 31 10 2019
pubmed: 16 11 2019
medline: 23 7 2021
entrez: 16 11 2019
Statut: ppublish

Résumé

Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, historically believed to affect 1 of 500 people. MYBPC3 pathogenic variations are the most frequent cause of familial HCM and more than 90% of them introduce a premature termination codon. The current study aims to determine the prevalence of deep intronic MYBPC3 pathogenic variations that could lead to splice mutations. To improve molecular diagnosis, a next-generation sequencing (NGS) workflow based on whole MYBPC3 sequencing of a cohort of 93 HCM patients, for whom no putatively causative point mutations were identified after NGS sequencing of a panel of 48 cardiomyopathy-causing genes, was performed. Our approach led us to reconsider the molecular diagnosis of six patients of the cohort (6.5%). These HCM probands were carriers of either a new large MYBPC3 rearrangement or splice intronic variations (five cases). Four pathogenic intronic variations, including three novel ones, were detected. Among them, the prevalence of one of them (NM_000256.3:c.1927+ 600 C>T) was estimated at about 0.35% by the screening of 1,040 unrelated HCM individuals. This study suggests that deep MYBPC3 splice mutations account for a significant proportion of HCM cases (6.5% of this cohort). Consequently, NGS sequencing of MYBPC3 intronic sequences have to be performed systematically.

Identifiants

pubmed: 31730716
doi: 10.1002/humu.23944
doi:

Substances chimiques

Carrier Proteins 0
RNA Splice Sites 0
myosin-binding protein C 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

465-475

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Références

Alfares, A. A., Kelly, M. A., McDermott, G., Funke, B. H., Lebo, M. S., Baxter, S. B., … Rehm, H. L. (2015). Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: Expanded panels offer limited additional sensitivity. Genetics in Medicine: Official Journal of the American College of Medical Genetics, 17(11), 880-888. https://doi.org/10.1038/gim.2014.205
Andrews, S. (2010). FastQC: A quality control tool for high throughput sequence data http://www.bioinformatics.babraham.ac.uk/projects/fastqc
Authors/Task Force members, Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., … Watkins, H. (2014). 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). European Heart Journal, 35(39), 2733-2779. https://doi.org/10.1093/eurheartj/ehu284
Bolger, A. M., Lohse, M., & Usadel, B. (2014). Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics (Oxford, England), 30(15), 2114-2120. https://doi.org/10.1093/bioinformatics/btu170
Burke, M. A., Cook, S. A., Seidman, J. G., & Seidman, C. E. (2016). Clinical and mechanistic insights into the genetics of cardiomyopathy. Journal of the American College of Cardiology, 68(25), 2871-2886. https://doi.org/10.1016/j.jacc.2016.08.079
Chanavat, V., Janin, A., & Millat, G. (2016). A fast and cost-effective molecular diagnostic tool for genetic diseases involved in sudden cardiac death. Clinica Chimica Acta, 453, 80-85. https://doi.org/10.1016/j.cca.2015.12.011
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., … Ruden, D. M. (2012). A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly, 6(2), 80-92. https://doi.org/10.4161/fly.19695
DePristo, M. A., Banks, E., Poplin, R., Garimella, K. V., Maguire, J. R., Hartl, C., … Daly, M. J. (2011). A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature Genetics, 43(5), 491-498. https://doi.org/10.1038/ng.806
Dimassi, S., Simonet, T., Labalme, A., Boutry-Kryza, N., Campan-Fournier, A., Lamy, R., … Lesca, G. (2015). Comparison of two next-generation sequencing kits for diagnosis of epileptic disorders with a user-friendly tool for displaying gene coverage, DeCovA. Applied & Translational Genomics, 7, 19-25. https://doi.org/10.1016/j.atg.2015.10.001
Frank-Hansen, R., Page, S. P., Syrris, P., McKenna, W. J., Christiansen, M., & Andersen, P. S. (2008). Micro-exons of the cardiac myosin binding protein C gene: Flanking introns contain a disproportionately large number of hypertrophic cardiomyopathy mutations. European Journal of Human Genetics: EJHG, 16(9), 1062-1069. https://doi.org/10.1038/ejhg.2008.52
Freund, M., Asang, C., Kammler, S., Konermann, C., Krummheuer, J., Hipp, M., … Schaal, H. (2003). A novel approach to describe a U1 snRNA binding site. Nucleic Acids Research, 31(23), 6963-6975. https://doi.org/10.1093/nar/gkg901
Geske, J. B., Ommen, S. R., & Gersh, B. J. (2018). Hypertrophic cardiomyopathy: Clinical update. JACC. Heart Failure, 6(5), 364-375. https://doi.org/10.1016/j.jchf.2018.02.010
Li, H. (2013). Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. ArXiv:1303.3997 [q-Bio]. Retrieved from http://arxiv.org/abs/1303.3997
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., … 1000 Genome Project Data Processing Subgroup (2009). The sequence alignment/map format and SAMtools. Bioinformatics (Oxford, England), 25(16), 2078-2079. https://doi.org/10.1093/bioinformatics/btp352
Lopes, L. R., Zekavati, A., Syrris, P., Hubank, M., Giambartolomei, C., Dalageorgou, C., … Elliott, P. M. (2013). Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. Journal of Medical Genetics, 50(4), 228-239. https://doi.org/10.1136/jmedgenet-2012-101270
Maron, B. J., & Maron, M. S. (2013). Hypertrophic cardiomyopathy. Lancet (London, England), 381(9862), 242-255. https://doi.org/10.1016/S0140-6736(12)60397-3
Millat, G., Bouvagnet, P., Chevalier, P., Dauphin, C., Jouk, P. S., Da Costa, A., … Rousson, R. (2010). Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. European Journal of Medical Genetics, 53(5), 261-267. https://doi.org/10.1016/j.ejmg.2010.07.007
Richard, P., Charron, P., Carrier, L., Ledeuil, C., Cheav, T., Pichereau, C., … EUROGENE Heart Failure Project (2003). Hypertrophic cardiomyopathy: Distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation, 107(17), 2227-2232. https://doi.org/10.1161/01.CIR.0000066323.15244.54
Seeger, T., Shrestha, R., Lam, C. K., Chen, C., McKeithan, W. L., Lau, E., … Wu, J. C. (2019). A premature termination codon mutation in MYBPC3 causes hypertrophic cardiomyopathy via chronic activation of nonsense-mediated decay. Circulation, 139(6), 799-811. https://doi.org/10.1161/CIRCULATIONAHA.118.034624
Semsarian, C., Ingles, J., Maron, M. S., & Maron, B. J. (2015). New perspectives on the prevalence of hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 65(12), 1249-1254. https://doi.org/10.1016/j.jacc.2015.01.019
Viswanathan, S. K., Sanders, H. K., McNamara, J. W., Jagadeesan, A., Jahangir, A., Tajik, A. J., & Sadayappan, S. (2017). Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage. PLOS One, 12(11), e0187948. https://doi.org/10.1371/journal.pone.0187948

Auteurs

Alexandre Janin (A)

Laboratoire de Cardiogénétique Moléculaire, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Lyon, France.
Institut NeuroMyoGène, CNRS UMR5310, INSERM U1217, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.

Valérie Chanavat (V)

Laboratoire de Cardiogénétique Moléculaire, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Lyon, France.
Institut NeuroMyoGène, CNRS UMR5310, INSERM U1217, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.

Pierre-Antoine Rollat-Farnier (PA)

Plateforme NGS-HCL, Cellule bioinformatique, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Lyon, France.

Claire Bardel (C)

Plateforme NGS-HCL, Cellule bioinformatique, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Lyon, France.
Laboratoire de Biométrie et Biologie Evolutive, Université de Lyon, Université Lyon 1, CNRS, Villeurbanne, France.
Service de Biostatistique-bioinformatique, Hospices Civils de Lyon, Lyon, France.

Karine Nguyen (K)

Département de Génétique Médicale, Hôpital d'enfants de la Timone, Marseille, France.

Philippe Chevalier (P)

Service de Rythmologie, Hôpital Cardiologique Louis-Pradel, Bron, France.
Université de Lyon, Lyon, France.

Jean-Christophe Eicher (JC)

Centre de Compétences des Cardiomyopathies, Hôpital d'Enfants, CHU de, Dijon, France.

Laurence Faivre (L)

Centre de Génétique, Centre Hospitalier Universitaire Dijon, Dijon, France.

Juliette Piard (J)

Centre de Génétique Humaine, Université de Franche-Comté, CHU Besançon, Besançon, France.
Unité de recherche en neurosciences intégratives et cognitives EA481, Université de Franche-Comté, Besançon, France.

Emma Albert (E)

Laboratoire de Cardiogénétique Moléculaire, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Lyon, France.
Institut NeuroMyoGène, CNRS UMR5310, INSERM U1217, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.

Severine Nony (S)

Laboratoire de Cardiogénétique Moléculaire, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Lyon, France.
Institut NeuroMyoGène, CNRS UMR5310, INSERM U1217, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.

Gilles Millat (G)

Laboratoire de Cardiogénétique Moléculaire, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Lyon, France.
Institut NeuroMyoGène, CNRS UMR5310, INSERM U1217, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH